Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Etoposide vs Daunorubicin in Low-risk APL
NCT05832320Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of etoposide in acute promyelocytic leukemia (APL) (2 arms), sponsored by Peking University People's Hospital. Primary endpoints: Complete remission at 45 days and Promyelocytic leukaemia-retinoic acid receptor alpha transcript levels at 45 days. Started Jan 2023; status: recruiting.
02
Drugs
etoposide
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT05832320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05832320.